In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.
The in vitro and in vivo activities of three newly developed quinolone antimicrobial agents (sparfloxacin, tosufloxacin, and OPC-17116) were investigated. All three agents showed potent in vitro activities against Chlamydia psittaci, C. trachomatis, and C. pneumoniae with MICs that ranged from 0.031 to 0.125 micrograms/ml. These values were higher than those of minocycline (0.0075 to 0.015 micrograms/ml) but lower than those of erythromycin (0.25 to 0.5 micrograms/ml) and ofloxacin and ciprofloxacin (0.5 to 1.0 micrograms/ml). Mice were challenged with 10(5) inclusion-forming units of C. psittaci each by nasal instillation. All untreated control animals died within 7 days. The survival rates of mice treated with 40 mg of sparfloxacin, OPC-17116, or tosufloxacin per kg of body weight every 12 h for 7 days were 73, 73, and 60%, respectively, 7 days after the challenge. The survival rate of mice treated with ofloxacin at the same dosage was 53%. On the basis of the above results, we concluded that these three new quinolones might be useful in the treatment of chlamydial respiratory infections.
Kimura
M
M
Department of Medicine, Kawasaki Medical School, Kurashiki, Japan.
Kishimoto
T
T
Niki
Y
Y
Soejima
R
R
D042462:4-Quinolones; D000818:Animals; D000890:Anti-Infective Agents / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D002689:Chlamydia / Q000187:drug effects*; D002690:Chlamydia Infections / Q000188:drug therapy* / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000187:drug effects; D016993:Chlamydophila pneumoniae / Q000187:drug effects; D002691:Chlamydophila psittaci / Q000187:drug effects; D015169:Colony Count, Microbial; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains
D042462:4-Quinolones; D000890:Anti-Infective Agents